SSSoraya Salcedo

Soraya Salcedo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soraya Salcedo has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Molecular Epidemiology and Clinical Characterization of Carbapenemase-Producing Enterobacter Species From an International Cohort

    by Jianping Jiang, Lauren Komarow, Carol Hill, Angelique E Boutzoukas, Blake Hanson, Cesar A Arias, Robert A Bonomo, Scott Evans, Yohei Doi, Michael J Satlin, et al.

    Background: Despite the global public health threat posed by carbapenem-resistant Enterobacter spp, clinical and molecular epidemiological studies on international isolates remain scarce. Historically, the taxonomy of Enterobacter has been challenging, limiting our understanding of the clinical characteristics and outcomes of carbapenemase-producing Enterobacter spp infections. Methods: Hospitalized patients enrolled in the CRACKLE-2 study (ClinicalTrials.gov, NCT03646227) from 2016 to 2018 with cultures positive for carbapenemase-producing Enterobacter spp were included. Clinical and microbiologic data were collected from health records. Whole genome sequencing was performed, and the population structures of selected predominant clones were analyzed. Results: We enrolled 136 hospitalized patients with carbapenemase-producing Enterobacter spp from 30 hospitals in 7 countries. Among the 136 isolates, 11 Enterobacter spp were identified, with most isolates belonging to E xiangfangensis (n = 81 [60%]) and E hoffmannii (n = 17 [13%]) and carrying blaKPC (n = 106 [78%]) and blaNDM (n = 12 [9%]). Clinical characteristics and outcomes were similar among patients with E xiangfangensis, E hoffmannii, or the other Enterobacter spp. Thirty-day mortality was 20%, and older age at enrollment (adjusted odds ratio, 1.42 [95% confidence interval, 1.08–1.87]) was associated with increased mortality. Sequence type (ST) 171 E xiangfangensis, ST78 E hoffmannii, and ST93 E xiangfangensis were the predominant clones, and the acquisition of fluoroquinolone resistance–associated mutations and carbapenemase-encoding plasmids contributed to their formation and global dissemination. Conclusions: Our findings demonstrate that E xiangfangensis and E hoffmannii are common species among international carbapenemase-producing Enterobacter spp, potentially linked to the clonal spread of a few predominant clones that have acquired fluoroquinolone resistance and carbapenemase-encoding plasmids.


  • Open Access

    Knowledge, attitudes, and behavior regarding antibiotics, antibiotic use, and antibiotic resistance in students and health care professionals of the district of Barranquilla (Colombia): A cross-sectional survey

    by S. Salcedo, L. Mora, D.A. Fernandez, A. Marín, I. Berrío, H. Mendoza-Charris, E.P. Viana-Cárdenas, M. Polo-Rodríguez, L. Muñoz-Garcia, J. Alvarez-Herrera, et al.


  • Open Access

    728. Genomic Characterization of Burkholderia pseudomallei Isolates in Colombia

    by Catalina Espitia-Acero, Rafael Rios, Monica Gabriela Huertas, Sandra Vargas, Carolina Duarte Valderrama, Jaime Moreno Castañeda, Jose Y Rodriguez, Carlos A Alvarez-Moreno, Nataly Camargo, Giovana Katherinne Casadiego-Santiago, et al.

    Melioidosis is a serious infection caused by Burkholderia pseudomallei (Bps), an opportunistic organism, highly adaptable and with a wide array of intrinsic virulence factors and antimicrobial resistance determinants. Bps is underdiagnosed due to its slow growth on routine laboratory media and the lack of robust diagnostic infrastructure in rural areas of low/middle income countries. Recent data indicates that Bps infections are increasing in Colombia (COL). However, the understanding of the genomic epidemiology and population structure of the emerging Bps isolates in COL is unknown. Here we characterize the genomic features of Bps isolates from infected patients in COL. We identified 13 Bps clinical isolates recovered in 5 Colombian cities between 2018 and 2020. We performed WGS and phylogenomic analyses using Bayesian methods. For comparisons, we included 82 publicly available genomes from Bps recovered worldwide (including 10 additional isolates from COL). Additionally, we characterized the resistome, virulome and MLST of all isolates. 12 out of the 13 isolates were confirmed as Bps and 1 belonged to the B. cepacia complex. The Bps population structure was divided in two main clades: clade 1 with isolates from Asia and Australia, and clade 2 with isolates from Africa, America, and the Caribbean (Figure 1). We found two groups of Colombian isolates, the first was related to ST518 and the second, highly diverse including 11 different STs (1742, 1748, 92, among others). Genomic characterization showed the presence of β-lactamases PenA (n=11) and OXA-57 (n=1). We also identified a T584A substitution in PBP3 (n=11). All genomes contained virulence determinants of motility (BimA), invasion (Flagella), signaling (CdpA) and adherence (Type IV pili). Type III and VI secretion systems, were also found in all isolates resembling Bps from other parts of the world. Figure 1. Maximum clade credibility tree of 82 genomes of Bps. The inner ring shows the ST for each genome, while the outer ring shows the geographical region associated with them. Groups highlighted in red show the location of the Colombian genomes and those related to them. Bps is an emerging pathogen in COL and its population structure seems highly diverse, predominantly of the American lineage and absence of Australasians strains. A high prevalence ( >90%) of resistance determinants, particularly related to β-lactams, suggest that active surveillance of these emergent pathogens is needed in countries like COL. Cesar A. Arias, M.D., MSc, Ph.D., FIDSA, Entasis Therapeutics (Grant/Research Support)MeMed Diagnostics (Grant/Research Support)Merk (Grant/Research Support) Lorena Diaz, PhD , Nothing to disclose

  • Open Access

    Determinación de E. coli biotipo 1 y E. coli O157:H7 en canal de carne bovina en plantas de beneficio del departamento del Atlántico (Colombia)

    by David Rosado-Porto, Jenifer Bonivento-Calvo, Soraya Salcedo-Mendoza, Ailen Molina-Castillo, Ronald Maestre-Serrano, Aracely Del Carmen García

    La contaminación de la canal con E. coli O157:H7, agente etiológico de la Enfermedad Diarreica Aguda (EDA), durante el sacrificio es la ruta primaria para la contaminación de la carne picada de vacuno. El objetivo del presente estudio fue determinar la prevalencia de E. coli biotipo 1 genérico y E. coli O157:H7 en bovinos sacrificados en plantas de beneficio del departamento del Atlántico. Se analizaron 224 canales de bovino provenientes de plantas de beneficio de cuatro municipios. Las muestras fueron procesadas en el Laboratorio de Salud Pública del departamento del Atlántico. Se determinó E. coli O157:H7 por el método VIDAS UP E. coli O157 (incluyendo H7) (ECPT) y E. coli biotipo 1, usando agar TBX (Oxoid), método ISO 16649-2:2000. La prevalencia de E. coli O157:H7 fue de 0.45% y de E. coli biotipo 1 genérico fue de 0.89% en muestras con recuentos de E. coli biotipo 1 >100 UFC/cm2. En 54% de las canales con presencia de E. coli, las concentraciones oscilaron entre 1 y 758 UFC/cm2. Se concluye que la prevalencia de E. coli O157:H7 encontrada fue baja (0.45%); sin embargo, indica presencia de esta cepa patógena en la zona, por lo que se requiere fortalecer la vigilancia para expendios y distribuidores.


  • Bloodstream Infections With Candida auris Among Children in Colombia: Clinical Characteristics and Outcomes of 34 Cases

    by Indira Berrio, Diego H Caceres, Wilfrido Coronell R, Soraya Salcedo, Laura Mora, Adriana Marin, Carmen Varón, Shawn R Lockhart, Patricia Escandón, Elizabeth L Berkow, et al.

    Background: Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014–October 2017 in 2 hospitals in Colombia. Methods: We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis. Results: We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged 1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19–33 days), and in-hospital mortality was 41%. Conclusions: Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals. Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcare-associated outbreaks. This report describes 34 cases of pediatric C. auris bloodstream infections, identified in two hospitals in Colombia, South America.


  • Open Access

    625. Genomic Epidemiology of Carbapenem-Resistant Enterobacteriaceae from Colombia: A Prospective Multicenter Study

    by Jinnethe Reyes, Lorena Diaz, Lina P Carvajal, Rafael Rios, Lina V Millan, Aura M Echeverri, Angie K Hernandez, Sandra Vargas, Soraya Salcedo, Adriana Marin, et al.

    Carbapenem-resistant Enterobacteriaceae (CRE) is a serious public health threat. A major epidemic of carbapenemase-producing Klebsiella pneumoniae has occurred in Colombia through complex mechanisms of blaKPC dissemination. In the framework of a prospective, observational cohort study (CRACKLE-2), we aimed to characterize the genomic epidemiology of CRE circulating in Colombia. We performed whole-genome sequencing of 52 isolates collected from the same number of patients (July 2017–April 2018) in 5 Colombian hospitals. Species confirmation and sequence type were determined using Strain Seeker and MLST database. Resistance genes were detected using ResFinder and CARD databases. Phylogenetic reconstruction included additional 108 isolates of carbapenem-resistant K. pneumoniae from a previous study. K. pneumoniae (36%), Escherichia coli (17%), and Enterobacter cloacae complex(17%) were the most frequent species. Genes conferring resistance to carbapenems were detected in 93% of isolates. blaKPC-2/3,blaNDM-1 andblaVIM-2/24 were identified in 81%, 15%, and 5% of isolates, respectively. Phylogenetic reconstructions of K. pneumoniae showed that clonal group 258 (CG258) were the predominant genetic lineage (Figure 1). Among CG258, ST11 was the most common comprising ca. 26% of isolates. Of note, ST11 had been extremely rare in previous surveillance studies in Colombia. The non-CG258 were from 9 different STs and exhibited high genomic diversity. Among E. coli isolates 33% belonged to the high-risk clone ST131 harboring blaKPC-2 and we detected both blaKPC-2 and blaVIM-24 in 1 E. coli ST131 isolate. ST510 E. cloacae complex harboring blaKPC-2 was the most common (44%) lineage. K. pneumoniae and E. coli are the most frequent CRE isolated from patients in Colombian hospitals. Dissemination of blaKPC through horizontal gene transfer to several species of Enterobacteriaceae continues to be a common mechanism of spread. Although KPC continues to be the most common carbapenemase, a rise in high-risk clonal lineages harboring metallo-carbapenemases, in particular NDM-1 is worrisome. Our results indicate emergence of virulent genetic lineages of K. pneumoniae ST11 and E. coli ST131 carrying carbapenemases in Colombia. All authors: No reported disclosures.